Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Gives The Stage To A New Generation Of Cancer Drugs

Executive Summary

With big oncology losses largely in the rearview mirror, Roche is trying to sell investors on its next wave of cancer drugs; R&D overview pushes message of pipeline renewal.

You may also be interested in...



Roche's SERD Setback Means Menarini Retains An Edge

Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.

Sanofi's SERD Candidate Founders In Advanced Breast Cancer

The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.

Readouts For TIGIT And Alzheimer’s Drugs Will Define Roche’s Year

Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel